Company news

Traws Pharma, Inc. news in 2024

Traws Pharma, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

December 29, 2024

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

December 22, 2024

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

November 13, 2024

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

October 7, 2024

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

September 29, 2024

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

September 19, 2024

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

September 16, 2024

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

August 14, 2024

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8: 00 AM ET

August 13, 2024

Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate

May 22, 2024

Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

May 6, 2024

Traws Pharma Announces New Employee Inducement Grants

April 1, 2024

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

April 1, 2024

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

March 7, 2024

Decks in 2024